期刊文献+

凝血纤溶指标测定在冠心病中的应用价值 被引量:2

The value of Detecting the coagulation fibrinolysis in the coronary artery disease
下载PDF
导出
摘要 测定了 2 1例急性心肌梗塞 (Acute myocardial infarction,AMI)、2 8例不稳定心绞痛(Unstable angina pectoris,UAP)和 2 0例正常对照者的血清纤维蛋白原 (Fibrinogen,Fg)、血浆 D-二聚体 (D- Dimer)、组织型纤溶酶原激活物 (Tissue- plasminogen,t- PA)及其抑制物(Plasminogen activator inhibitor,PAI)活性 ,并观察了 AMI患者溶栓前后它们的变化。结果 :1AMI、UAP患者血浆 t- PA活性降低 ,PAI活性增高 ,D- Dimer、Fg含量增多 ,提示凝血纤溶系统功能异常在冠心病 (CHD)发病中有重要作用 ,UAP和 AMI有共同的血栓倾向或血栓形成机制。 2 AMI患者溶栓后血清 Fg含量下降 ,D- Dimer含量升高 ,t- PA活性增强 ,PAI活性下降 。 In order to make clear the relationship between the change of coagulation fibrinolysis and the developing,treatment effects of coronary heart disease (CHD),serious fibrinogen (Fg) was measured ,plasimic D Dimer,tissue type plasmiogen activator (t PA) and its inhibitor plasminogen activator inhibitor (PAI) by using Enzyme Assay Meter in 21patients with acute myocardial infarction(AMI) ,28 with unstable angina pectroris(UAP) and 20 control subjects,the changes of the four indicators before and after thromboclasis in patients with AMI were also examined.The results showed that:①In the patients with AMI and UAP, the activity of plasmic t PA decreased while PAI increased, the levels of D Dimer and Fg were higher.which indicated the system of coagulation fibrinolysis played an important role in the developing of CHD because of the trend and forming of thrombus in UAP and AMI;②After thromboclasis ,the levels of serious Fg were lower, D Dimer were higher ,the activity of t PA increased while the activity of PAI decreased, which were close related to recanalization of coronary infarction.
出处 《西安医科大学学报》 CSCD 2000年第2期112-114,共3页 Journal of Xi'an Medical University(Chinese)
关键词 急性心肌梗塞 冠心病 凝血纤溶系统 coagulation fibrinolysis AMI UAP thromboclasis treatment
  • 相关文献

参考文献4

二级参考文献1

  • 1丁文惠,中华心血管病杂志,1993年,20卷,80页

共引文献95

同被引文献19

  • 1国家药品监督管理局.中药新药临床研究指导原则.北京:中国医药科技出版社,2004:68-73.
  • 2王振义,李家增,阮长耿,等.血栓与止血基础理论与临床.2版.上海:上海科学技术出版社,2001:63.
  • 3Cavusoglu Y. Gorenek B, Alpsoy S, et al. Evaluation of C-reactive Protein fibrinogen and antithrombin-Ⅲ as risk factors for coronary artery disease. Isr Med Assac J, 2004,3:13 - 16.
  • 4Zarebin G,Ski M, Olszewski R, et al. Fibrinogen serunl levels in patients with stable coronary artery disease and acute coronary syndrome. Pol Merkuriusz Lek, 2003,50:531 - 532.
  • 5Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thronlbosis. Semin Hematol ,2002 ,29 :177 - 188.
  • 6Shainoff JR, Urbanic DA, DiBello PM ,et al. Immunoelectrophoretie characterizations of the cross-1 inking of fibrinogen and fibrin by factor Ⅹ Ⅲ a and tissue thransglutaminase. J Biol Chem, 2001, 266: 6429 - 6437.
  • 7Mosesson MW. Fibrin polymerization and its regulatory role in hemostasis. J Lab Clin Med, 2002,116:8 -17.
  • 8[1]国家药品监督管理局.中药新药临床研究指导原则.北京:中国医药科技出版社,2002.68-73.
  • 9[3]Cavusoglu Y,Gorenek B,Alpsoy S,et al.Evaluation of C-reactive protein,fibrinogen and antithrombin-III as risk factors for coronary artery disease.Isr Med Assoc J,2001,3(1):13-16.
  • 10[4]Gil M,Zarebinski M,Olszewski R,et al.Fibrinogen serum levels in patients with stable coronary artery disease and acute coronary syndrome.Pol Merkuriusz Lek,2000,9(50):531-532.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部